<p>Voloridge Investment Management LLC 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在 10x Genomics, Inc. (NASDAQ:TXG - 免费报告) 的持股比例提高了 12.1%。该公司在此期间购买了额外的 171,161 股后，持有 1,585,965 股该公司的股票。根据其最近的 SEC 文件，Voloridge Investment Management LLC 持有 10x Genomics 1.31% 的股份，价值 22,774,000 美元。</p>
<ul>
<li>战略性买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也调整了对 TXG 的持股。RA Capital Management L.P. 在第四季度购买了 10x Genomics 的新股份，价值约 47,092,000 美元。D. E. Shaw &amp; Co. Inc. 在第四季度购买了 10x Genomics 的新股份，估计价值约 17,499,000 美元。ARK Investment Management LLC 在第四季度将其在 10x Genomics 的持股比例提高了 11.1%。ARK Investment Management LLC 目前持有 11,944,057 股该公司的股票，价值 171,517,000 美元，此前在上个季度购买了额外的 1,193,712 股。Two Sigma Investments LP 在第四季度将其在 10x Genomics 的持股比例提高了 291.2%。Two Sigma Investments LP 目前持有 1,319,487 股该公司的股票，价值 18,948,000 美元，此前在上个季度购买了额外的 982,203 股。最后，Two Sigma Advisers LP 在第四季度将其在 10x Genomics 的持股比例提高了 240.6%。Two Sigma Advisers LP 目前持有 1,236,200 股该公司的股票，价值 17,752,000 美元，此前在上个季度购买了额外的 873,200 股。84.68% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师最近对该公司发表了看法。瑞银集团将 10x Genomics 的目标股价从 14.00 美元下调至 12.00 美元，并在 5 月 13 日的研究报告中对该股票给予了 “中性” 评级。Stifel Nicolaus 将 10x Genomics 的目标股价从 21.00 美元下调至 18.00 美元，并在 2 月 13 日的报告中对该股票给予了 “买入” 评级。Stephens 在 5 月 15 日的报告中重申了 “增持” 评级，并对 10x Genomics 的股票设定了 14.00 美元的目标股价。Leerink Partners 将 10x Genomics 的股票评级从 “跑赢大盘” 下调至 “市场表现”，并在 2 月 13 日的报告中将其目标股价从 25.00 美元下调至 12.00 美元。最后，高盛集团将 10x Genomics 的目标股价从 7.50 美元下调至 6.50 美元，并在 5 月 12 日的报告中对该股票给予了 “卖出” 评级。一位研究分析师对该股票给予了卖出评级，八位分析师给予了持有评级，八位分析师给予了买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价为 15.81 美元。</p>
<p><strong>查看我们对 10x Genomics 的最新股票分析</strong></p>
<h2>10x Genomics 的内部买卖</h2>
<p>在其他新闻中，内部人士 Benjamin J. Hindson 于 2 月 24 日星期一出售了 4,573 股该公司的股票。该股票以平均价格 11.07 美元出售，总价值为 50,623.11 美元。交易后，内部人士现在直接持有 335,324 股该公司的股票，价值 3,712,036.68 美元。此交易代表其持股比例减少了 1.35%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，首席执行官 Serge Saxonov 于 2 月 24 日星期一出售了 5,092 股该公司的股票。该股票以平均价格 11.07 美元出售，总价值为 56,368.44 美元。交易完成后，首席执行官现在持有 879,482 股该公司的股票，价值约 9,735,865.74 美元。此交易代表其持股比例减少了 0.58%。该销售的披露信息可以在这里找到。公司内部人士持有该公司 9.39% 的股票。</p>
<h2>10x Genomics 股票上涨 2.6%</h2>
<p>NASDAQ TXG 的股票在周五开盘时为 8.54 美元。10x Genomics, Inc. 的 12 个月低点为 6.78 美元，12 个月高点为 24.76 美元。该公司的市值为 10.4 亿美元，市盈率为 -5.62，贝塔值为 1.94。该公司的 50 日移动平均线为 8.63 美元，200 日移动平均线为 12.15 美元。</p>
<p>10x Genomics (NASDAQ:TXG - 获取免费报告) 最近于 5 月 8 日宣布了其季度财报。该公司报告本季度每股收益为（0.36）美元，超过分析师一致预期的（0.45）美元，超出幅度为 0.09 美元。10x Genomics 的净利润率为 -29.90%，股本回报率为 -25.40%。该公司本季度的收入为 1.5488 亿美元，而分析师预期为 1.3191 亿美元。在去年同期，该公司的每股收益为（0.50）美元。该公司的季度收入同比下降了 2.3%。整体来看，股票分析师预计 10x Genomics, Inc. 在当前财年将发布 -1.43 的每股收益。</p>
<h2>10x Genomics 公司简介</h2>
<p>（免费报告）</p>
<p>10x Genomics, Inc. 是一家生命科学技术公司，开发和销售用于分析生物系统的仪器、耗材和软件，业务覆盖美国、欧洲、中东、非洲、中国和亚太地区。该公司提供 chromium、chromium connect 和 chromium controller 仪器、微流控芯片、载玻片、试剂和其他耗材产品。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 10x Genomics</li>
<li>三只值得购买的医疗保健分红股票</li>
<li>Joby 股票的波动：近期下跌的原因是什么？</li>
<li>经纪评级在股票选择中的重要性</li>
<li>为什么嘉年华可能是终极非科技增长股票</li>
<li>股票情绪分析：它是如何运作的</li>
<li>超级微型计算机股票在沙特订单中开辟新路径</li>
</ul>
<p><strong>想知道其他对 TXG 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com 获取 10x Genomics, Inc. (NASDAQ:TXG - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFhH?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFhH"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 10x Genomics 吗？</h2>
<p>在考虑投资 10x Genomics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 10x Genomics 并不在名单上。</p>
<p>虽然 10x Genomics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Voloridge Investment Management LLC 在第四季度将其在 10X Genomics, Inc. (NASDAQ:TXG) 的持股增加了 12.1%，目前拥有 1,585,965 股，价值 2277 万美元。其他机构投资者也增加了他们的持股。分析师对该股票的评级不一，普遍目标价为 15.81 美元。10X Genomics 的股票最近上涨了 2.6%，交易价格为 8.54 美元，市值为 10.4 亿美元，市盈率为 -5.62</p>

<p>Voloridge Investment Management LLC lifted its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 12.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,585,965 shares of the company's stock after purchasing an additional 171,161 shares during the period. Voloridge Investment Management LLC owned 1.31% of 10x Genomics worth $22,774,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Voloridge Investment Management LLC 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在 10x Genomics, Inc. (NASDAQ:TXG - 免费报告) 的持股比例提高了 12.1%。该公司在此期间购买了额外的 171,161 股后，持有 1,585,965 股该公司的股票。根据其最近的 SEC 文件，Voloridge Investment Management LLC 持有 10x Genomics 1.31% 的股份，价值 22,774,000 美元。</p>
</div><ul>
<li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li>
</ul>
<div class="lb-trans"><ul>
<li>战略性买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of TXG. RA Capital Management L.P. purchased a new stake in shares of 10x Genomics in the 4th quarter worth about $47,092,000. D. E. Shaw &amp; Co. Inc. bought a new stake in shares of 10x Genomics during the fourth quarter valued at approximately $17,499,000. ARK Investment Management LLC boosted its position in shares of 10x Genomics by 11.1% during the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company's stock valued at $171,517,000 after purchasing an additional 1,193,712 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of 10x Genomics by 291.2% during the fourth quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock valued at $18,948,000 after purchasing an additional 982,203 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its position in shares of 10x Genomics by 240.6% during the fourth quarter. Two Sigma Advisers LP now owns 1,236,200 shares of the company's stock valued at $17,752,000 after purchasing an additional 873,200 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也调整了对 TXG 的持股。RA Capital Management L.P. 在第四季度购买了 10x Genomics 的新股份，价值约 47,092,000 美元。D. E. Shaw &amp; Co. Inc. 在第四季度购买了 10x Genomics 的新股份，估计价值约 17,499,000 美元。ARK Investment Management LLC 在第四季度将其在 10x Genomics 的持股比例提高了 11.1%。ARK Investment Management LLC 目前持有 11,944,057 股该公司的股票，价值 171,517,000 美元，此前在上个季度购买了额外的 1,193,712 股。Two Sigma Investments LP 在第四季度将其在 10x Genomics 的持股比例提高了 291.2%。Two Sigma Investments LP 目前持有 1,319,487 股该公司的股票，价值 18,948,000 美元，此前在上个季度购买了额外的 982,203 股。最后，Two Sigma Advisers LP 在第四季度将其在 10x Genomics 的持股比例提高了 240.6%。Two Sigma Advisers LP 目前持有 1,236,200 股该公司的股票，价值 17,752,000 美元，此前在上个季度购买了额外的 873,200 股。84.68% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts recently weighed in on the company. UBS Group dropped their price target on 10x Genomics from $14.00 to $12.00 and set a &#34;neutral&#34; rating on the stock in a research report on Tuesday, May 13th. Stifel Nicolaus cut their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a &#34;buy&#34; rating on the stock in a report on Thursday, February 13th. Stephens restated an &#34;overweight&#34; rating and issued a $14.00 price objective on shares of 10x Genomics in a report on Thursday, May 15th. Leerink Partners cut shares of 10x Genomics from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and cut their price objective for the stock from $25.00 to $12.00 in a report on Thursday, February 13th. Finally, The Goldman Sachs Group cut their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a &#34;sell&#34; rating on the stock in a report on Monday, May 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus price target of $15.81.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发表了看法。瑞银集团将 10x Genomics 的目标股价从 14.00 美元下调至 12.00 美元，并在 5 月 13 日的研究报告中对该股票给予了 “中性” 评级。Stifel Nicolaus 将 10x Genomics 的目标股价从 21.00 美元下调至 18.00 美元，并在 2 月 13 日的报告中对该股票给予了 “买入” 评级。Stephens 在 5 月 15 日的报告中重申了 “增持” 评级，并对 10x Genomics 的股票设定了 14.00 美元的目标股价。Leerink Partners 将 10x Genomics 的股票评级从 “跑赢大盘” 下调至 “市场表现”，并在 2 月 13 日的报告中将其目标股价从 25.00 美元下调至 12.00 美元。最后，高盛集团将 10x Genomics 的目标股价从 7.50 美元下调至 6.50 美元，并在 5 月 12 日的报告中对该股票给予了 “卖出” 评级。一位研究分析师对该股票给予了卖出评级，八位分析师给予了持有评级，八位分析师给予了买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价为 15.81 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on 10x Genomics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 10x Genomics 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling at 10x Genomics</h2>
<div class="lb-trans"><h2>10x Genomics 的内部买卖</h2>
</div><p>In other news, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now directly owns 335,324 shares in the company, valued at $3,712,036.68. This trade represents a 1.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Serge Saxonov sold 5,092 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares in the company, valued at approximately $9,735,865.74. This trade represents a 0.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.39% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Benjamin J. Hindson 于 2 月 24 日星期一出售了 4,573 股该公司的股票。该股票以平均价格 11.07 美元出售，总价值为 50,623.11 美元。交易后，内部人士现在直接持有 335,324 股该公司的股票，价值 3,712,036.68 美元。此交易代表其持股比例减少了 1.35%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，首席执行官 Serge Saxonov 于 2 月 24 日星期一出售了 5,092 股该公司的股票。该股票以平均价格 11.07 美元出售，总价值为 56,368.44 美元。交易完成后，首席执行官现在持有 879,482 股该公司的股票，价值约 9,735,865.74 美元。此交易代表其持股比例减少了 0.58%。该销售的披露信息可以在这里找到。公司内部人士持有该公司 9.39% 的股票。</p>
</div><h2>10x Genomics Stock Up 2.6%</h2>
<div class="lb-trans"><h2>10x Genomics 股票上涨 2.6%</h2>
</div><p>Shares of NASDAQ TXG opened at $8.54 on Friday. 10x Genomics, Inc. has a twelve month low of $6.78 and a twelve month high of $24.76. The firm has a market cap of $1.04 billion, a P/E ratio of -5.62 and a beta of 1.94. The company has a 50 day moving average of $8.63 and a 200 day moving average of $12.15.</p>
<div class="lb-trans"><p>NASDAQ TXG 的股票在周五开盘时为 8.54 美元。10x Genomics, Inc. 的 12 个月低点为 6.78 美元，12 个月高点为 24.76 美元。该公司的市值为 10.4 亿美元，市盈率为 -5.62，贝塔值为 1.94。该公司的 50 日移动平均线为 8.63 美元，200 日移动平均线为 12.15 美元。</p>
</div><p>10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The company had revenue of $154.88 million during the quarter, compared to analyst estimates of $131.91 million. During the same period in the previous year, the business earned ($0.50) EPS. The firm's revenue for the quarter was down 2.3% on a year-over-year basis. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>10x Genomics (NASDAQ:TXG - 获取免费报告) 最近于 5 月 8 日宣布了其季度财报。该公司报告本季度每股收益为（0.36）美元，超过分析师一致预期的（0.45）美元，超出幅度为 0.09 美元。10x Genomics 的净利润率为 -29.90%，股本回报率为 -25.40%。该公司本季度的收入为 1.5488 亿美元，而分析师预期为 1.3191 亿美元。在去年同期，该公司的每股收益为（0.50）美元。该公司的季度收入同比下降了 2.3%。整体来看，股票分析师预计 10x Genomics, Inc. 在当前财年将发布 -1.43 的每股收益。</p>
</div><h2>10x Genomics Profile</h2>
<div class="lb-trans"><h2>10x Genomics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.</p>
<div class="lb-trans"><p>10x Genomics, Inc. 是一家生命科学技术公司，开发和销售用于分析生物系统的仪器、耗材和软件，业务覆盖美国、欧洲、中东、非洲、中国和亚太地区。该公司提供 chromium、chromium connect 和 chromium controller 仪器、微流控芯片、载玻片、试剂和其他耗材产品。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than 10x Genomics</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Turbulence for Joby Shares: What's Behind the Recent Dip?</li>
<li>The Significance of Brokerage Rankings in Stock Selection</li>
<li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Super Micro Computer Stock Clears New Path Higher on Saudi Orders</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 10x Genomics</li>
<li>三只值得购买的医疗保健分红股票</li>
<li>Joby 股票的波动：近期下跌的原因是什么？</li>
<li>经纪评级在股票选择中的重要性</li>
<li>为什么嘉年华可能是终极非科技增长股票</li>
<li>股票情绪分析：它是如何运作的</li>
<li>超级微型计算机股票在沙特订单中开辟新路径</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TXG?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXG - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 TXG 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com 获取 10x Genomics, Inc. (NASDAQ:TXG - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFhH" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TXG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in 10x Genomics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 10x Genomics 吗？</h2>
</div><p>Before you consider 10x Genomics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 10x Genomics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 10x Genomics 并不在名单上。</p>
</div><p>While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 10x Genomics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Voloridge Investment Management LLC 增持了 10x Genomics, Inc.（NASDAQ:TXG）的股份